Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
Public ClinicalTrials.gov record NCT02136940. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Multicenter, Randomized, Double-masked, Placebo-controlled, Parallel-group Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Study identification
- NCT ID
- NCT02136940
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Amakem, NV
- Industry
- Enrollment
- 103 participants
Conditions and interventions
Conditions
Interventions
- AMA0076 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 30 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2014
- Primary completion
- Oct 31, 2014
- Completion
- Nov 30, 2014
- Last update posted
- Jan 20, 2015
2014
United States locations
- U.S. sites
- 9
- U.S. states
- 4
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Artesia Clinical - Site 11 | Artesia | California | — | — |
| Inglewood Clinical Site - Site 15 | Inglewood | California | — | — |
| Petaluma Clinical Site - Site 17 | Petaluma | California | — | — |
| Morrow Clinical Site - Site13 | Morrow | Georgia | — | — |
| Roswell Clinical Site - Site 18 | Roswell | Georgia | — | — |
| Rochester Clinical Site - Site 12 | Rochester | New York | — | — |
| Slingerlands Clinical Site - Site 19 | Slingerlands | New York | — | — |
| Charlotte Clinical Site - Site 14 | Charlotte | North Carolina | — | — |
| High Point Clinical Site - Site 16 | High Point | North Carolina | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02136940, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 20, 2015 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02136940 live on ClinicalTrials.gov.